A 2020 randomized trial reported no difference in 90-day mortality among patients 65 years or older with vasodilatory hypotension randomized to vasopressor treatment to a mean arterial pressure (MAP) target of 60-65 mm Hg (permissive hypotension) vs treatment at the clinician’s discretion. Francois Lamontagne, MD, of the Universite de Sherbrooke in Quebec, Canada, presented findings from the 65 Trial at the Critical Care Reviews 2020 meeting (CCR20), on January 17 in Belfast, Northern Ireland. An oral editorial from Anders Perner, MD, PhD, of Copenhagen University Hospital and a Q&A session follow. Click the related article link for full trial details. Video used with permission.
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
You currently have no searches saved.
You currently have no courses saved.